Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

To get a sense of who is truly in control of Amgen Inc. (NASDAQ:AMGN), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP-1 drugs, it targets a hormone that slows stomach emptying. Over 12 weeks, ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Retired pro football hall-of-famer Barry Sanders revealed he had a heart attack in 2024. But now he working to help other ...

Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...

Ligand Pharmaceuticals offers investors exposure to dozens of therapies, reducing risk and increasing upside potential. See ...

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...